Nonalcoholic steatohepatitis (NASH)
Drug research and approvals for nonalcoholic steatohepatitis (NASH): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 198 studies of nonalcoholic steatohepatitis (NASH) are recruiting on ClinicalTrials.gov, and Health Canada has authorized 44 drug trials for it since 2013.
- Recruiting worldwide: 198
- Trials authorized in Canada: 44
- FDA orphan approvals: 0
- EU medicines: 0
- High-Plant-Protein-Diet or High-Animal-Protein-Diet for Improving Alcoholic Fatty Liver DiseaseNCT07897981 · Phase 1 / Phase 2 · Li Lab,MD · starts Oct 10, 2026
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT07854782 · Phase 3 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- Metaboic Syndrome and Fatty Liver in Celiac Disease Females: Reponse to Exercise in AdolescentsNCT07832994 · Not applicable · Cairo University · starts Aug 15, 2026
- NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)NCT07820800 · Not applicable · University of Eastern Finland · starts Sep 1, 2026
- Study of ECC4703 With Sulfasalazine and PitavastatinNCT07726368 · Phase 1 · Eccogene · starts Aug 7, 2026
- Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLDNCT07692438 · Not applicable · Taipei Medical University · starts May 28, 2025
- Dihydroartemisinin for MAFLDNCT07679542 · Phase 1 / Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Mar 30, 2026
- Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With ObesityNCT07662356 · Not reported · Chinese University of Hong Kong · starts Dec 16, 2019
- Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek ProgrammeNCT07658755 · Not reported · Hospital General Universitario Gregorio Marañon · starts Oct 1, 2024
| Apr 9, 2026 | Phase 2, randomized, double-blind, placebo-controlled study to evaluate MGL-3196 (resmetirom) in patients with MASH who have undergone liver transplant for…Resmetirom (MGL-3196) | Madrigal Pharmaceuticals | Pending |
| Aug 26, 2024 | A randomised, double-blind, placebo-controlled, multicentre, phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult…Survodutide (bi 456906) | Boehringer Ingelheim Pharmaceuticals | Ongoing |
| Aug 26, 2024 | A phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in…Survodutide (bi 456906) | Boehringer Ingelheim Pharmaceuticals | Ongoing |
| Jul 5, 2024 | A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with compensated cirrhosis due to…Efruxifermin | Akero Therapeutics | Ongoing |
| Aug 17, 2023 | A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-cirrhotic nonalcoholic…Efruxifermin (EFX) | Akero Therapeutics | Ongoing |
| May 30, 2023 | A phase 2b randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of efinopegdutide (MK-6024) in adults with…Efinopegdutide (MK-6024) / Wegovy (semaglutide) | Merck & Co. (MSD) | Ongoing |
| Feb 23, 2023 | A randomized double-blind placebo-controlled phase 3 study to evaluate the effect of resmetirom on liver-related outcomes in patients with well-compensated…Resmetirom (MGL-3196) | Madrigal Pharmaceuticals | Ongoing |
| Feb 17, 2023 | Investigation of pharmacokinetics following administration of NNC0194-0499 and semaglutide as co-formulation versus separate injections in healthy participantsNNC0194-0499 b / Semaglutide b / NNC0194-0499 semaglutide a | Novo Nordisk | Closed |
| Nov 30, 2022 | 17b-hydroxysteroid dehydrogenase type 13 minimization for the treatment of NASH (HORIZON): a double-blind, placebo-controlled phase 2b study to evaluate the…GSK4532990 | GSK | Closed |
| Apr 7, 2022 | A phase 2, multicenter, placebo-controlled, randomized, double-blind, 48-week study to evaluate the efficacy and safety of combination therapy of K-877-er and…Pemafibrate (K-877) / Tofogliflozin (CSG452) | Kowa Research Institute, Inc | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA